Simulations Plus, Inc. (SLP)
Healthcare
- Fundamental
- 4
- Sentiment
- 3
- Technical
- 4
Do Nothing: avgDollarVolume20 is 4642725.89, below the required 5000000 liquidity floor. Price and fundamental gates pass, and the confirmed 2026-07-13 earnings date is outside the blackout window, but this takeover-driven spike is not actionable for this 1-15 day long strategy and upside is crowded near the $18.50 cash-deal price.
Company overview
Simulations Plus, Inc. develops software and services to enhance drug discovery and development. It uses AI and machine learning for modeling and simulation tools that predict molecular characteristics. The company serves pharmaceutical, biotechnology, and other industries globally.
Fundamental
goodSimulations Plus maintains strong liquidity and cash generation, though recent impairments distort profitability.
Strong liquidity and net-cash balance sheet, with operating cash flow remaining positive even through an impairment-heavy FY2025. Recent quarterly results show improving profitability and healthy gross margins, but trailing GAAP margins are distorted by a $77.2M goodwill/intangible impairment and the dividend has been suspended. A June 2026 all-cash acquisition agreement at $18.50/share limits upside and makes deal completion the key near-term variable.
Sentiment
fairSentiment is influenced by the pending acquisition, with media coverage skewed by low-signal legal solicitations.
Dominant driver is the $18.50/share all-cash acquisition (issuer 8-K noted upstream on 2026-06-16 treated as regulator_confirmed), leaving SLP trading mostly as a deal-spread while last ~14d headlines skew bearish and low-signal due to a burst of plaintiff-law-firm “investigation/fair price” releases. Baseline coverage (30–90d) is too sparse to quantify a sentiment delta, and legal scans show no regulator-confirmed investigation (only marketing solicitations), so no severe red flags.
Technical
goodThe stock shows a bullish trend but is constrained by takeover dynamics, limiting further upside.
TechnicalScore 4/5 on chart quality alone: price ripped above SMA20/50/200 and EMA9/21 on a large catalyst-driven expansion, MACD is positive and above signal, RSI14 at 68.40 confirms momentum, and ADX14 at 46.12 shows a strong trend. The weak spots are short-term extension (Williams %R -9.62), a close just under daily VWAP 18.32, and the fact that the move is pinned near the upstream-noted $18.50 cash-takeout level.
You’re looking at 2026-06-16 — about 2 trading days ago.
Subscribers saw this then, and see today’s score, verdict and trade plan now.
More Healthcare
Not financial advice. For informational and educational purposes only.